NASDAQ:UTHR
United Therapeutics Corporation Stock News
$266.22
+5.71 (+2.19%)
At Close: May 07, 2024
United Therapeutics Announces First Patient Enrolled In Phase 3 TETON Study Of Tyvaso In Patients With Idiopathic Pulmonary Fibrosis
06:00am, Thursday, 03'rd Jun 2021
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
Bernard Horn's Top 5 Trades of the 1st Quarter
05:26pm, Tuesday, 01'st Jun 2021
Bernard Horn (Trades, Portfolio), manager of the Polaris Global Value Fund, disclosed last week that his firms top five trades during the first quarter included new positions in United Therapeutics Co
United Therapeutics Corporation To Present At The Jefferies Virtual Healthcare Conference
06:00am, Tuesday, 25'th May 2021
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q1 2021 Results - Earnings Call Transcript
01:55pm, Wednesday, 05'th May 2021
United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q1 2021 Results - Earnings Call Transcript
United Therapeutics (UTHR) Lags Q1 Earnings Estimates
08:39am, Wednesday, 05'th May 2021
United Therapeutics (UTHR) delivered earnings and revenue surprises of -76.54% and 3.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics Corporation Reports First Quarter 2021 Financial Results
06:00am, Wednesday, 05'th May 2021
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
United Therapeutics Corporation To Report First Quarter 2021 Financial Results Before The Market Opens On Wednesday, May 5, 2021
06:00am, Monday, 26'th Apr 2021
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
United Therapeutics (UTHR) Gains on Tyvaso Label Expansion
09:05am, Monday, 05'th Apr 2021
United Therapeutics' (UTHR) Tyvaso is now the only FDA-approval therapy for treating serious, life-threatening disease, pulmonary hypertension associated with interstitial lung disease.
This Pharma Can Breathe New Life Into Your Portfolio
06:50am, Friday, 02'nd Apr 2021
Will future Tyvaso revenue growth push United Therapeutics to new heights?
United Therapeutics Stock Price Increased Over 10% Pre-Market: Why It Happened
08:58am, Thursday, 01'st Apr 2021
The stock price of United Therapeutics Corporation (Nasdaq: UTHR) increased by over 10% pre-market. This is why it happened.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
United Therapeutics Corporation To Present At The 10th Annual J.P. Morgan Napa Valley Forum
06:00am, Wednesday, 24'th Mar 2021
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
United Therapeutics Pulls Plug On Trevyent Development
07:38am, Wednesday, 03'rd Mar 2021
Based on the FDA's written comments, United Therapeutics Corporation (NASDAQ: UTHR) has decided to discontinue the development of Trevyent. Trevyent is a drug-device combination product that comb
United Therapeutics (UTHR) Q4 Earnings Miss, Sales Beat
09:09am, Thursday, 25'th Feb 2021
United Therapeutics' (UTHR) fourth-quarter earnings miss estimates while sales beat the same. Higher sales of Orenitram, Remodulin and Tyvaso offset lower sales of Unituxin and Adcirca.
United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q4 2020 Results - Earnings Call Transcript
02:37pm, Wednesday, 24'th Feb 2021
United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q4 2020 Results - Earnings Call Transcript
